• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Development of oral iron chelator L1.

作者信息

Hershko C

出版信息

Lancet. 1993 Apr 24;341(8852):1088-9. doi: 10.1016/0140-6736(93)92444-x.

DOI:10.1016/0140-6736(93)92444-x
PMID:8096975
Abstract
摘要

相似文献

1
Development of oral iron chelator L1.
Lancet. 1993 Apr 24;341(8852):1088-9. doi: 10.1016/0140-6736(93)92444-x.
2
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.一项使用心血管磁共振评估去铁胺与去铁酮联合治疗对重型地中海贫血患者心肌铁影响的随机、安慰剂对照、双盲试验。
Circulation. 2007 Apr 10;115(14):1876-84. doi: 10.1161/CIRCULATIONAHA.106.648790. Epub 2007 Mar 19.
3
[Iron chelation in 1998].
Transfus Clin Biol. 1998 Oct;5(5):353-6. doi: 10.1016/s1246-7820(98)85006-4.
4
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）治疗重型地中海贫血的疗效及可能的不良反应
Blood. 1992 Aug 1;80(3):593-9.
5
Pharmacotherapy of iron overload in thalassaemic patients.地中海贫血患者铁过载的药物治疗
Expert Opin Pharmacother. 2003 Oct;4(10):1763-74. doi: 10.1517/14656566.4.10.1763.
6
The controversial role of deferiprone in the treatment of thalassemia.去铁酮在治疗地中海贫血中存在争议的作用。
J Lab Clin Med. 2001 May;137(5):324-9. doi: 10.1067/mlc.2001.114105.
7
Deferiprone: New insight.去铁酮：新见解。
Ann N Y Acad Sci. 2005;1054:169-74. doi: 10.1196/annals.1345.019.
8
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.去铁胺、去铁酮和地拉罗司铁螯合疗法治疗非输血依赖型地中海贫血综合征铁过载患者的疗效和安全性。
Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016.
9
Oral iron chelation therapy for thalassaemia: an uncertain scene.地中海贫血的口服铁螯合疗法：前景不明。
Br J Haematol. 2000 Oct;111(1):2-5. doi: 10.1046/j.1365-2141.2000.02406.x.
10
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.使用去铁酮（L1）、去铁胺的ICOC联合治疗方案及新型螯合药物对地中海贫血铁过载进行有效新治疗。
Haematologica. 2006 Jun;91(6 Suppl):ELT04.

引用本文的文献

1
Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.地拉罗司和铁-麦芽酚：从发现到药物设计、研发、临床应用及未来前景的四十年。
Int J Mol Sci. 2023 Mar 4;24(5):4970. doi: 10.3390/ijms24054970.
2
The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.去铁酮（L1）的历史及地中海贫血铁过载完全治疗的范例
Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020011. doi: 10.4084/MJHID.2020.011. eCollection 2020.
3
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.
全球健康困境：孤儿病与罕见病、孤儿药与孤儿患者
World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.
4
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.去铁酮治疗地中海贫血及其他病症铁过载的获益与风险：与去铁胺的流行病学及治疗学方面比较
Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003.
5
Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study.
Mol Cell Biochem. 2000 Jan;204(1-2):17-20. doi: 10.1023/a:1007049701572.
6
Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.地中海贫血及其他疾病中口服铁螯合疗法的现状与未来前景
Indian J Pediatr. 1993 Jul-Aug;60(4):485-507. doi: 10.1007/BF02751425.
7
Iron chelators as therapeutic agents against Pneumocystis carinii.铁螯合剂作为抗卡氏肺孢子虫的治疗药物。
Antimicrob Agents Chemother. 1994 May;38(5):997-1003. doi: 10.1128/AAC.38.5.997.